Hu Jin, Tan Jie, Dong Fang, Zhang Ximeng, Ming Jie, Huang Tao
Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Oncol. 2022 Jan 12;11:593121. doi: 10.3389/fonc.2021.593121. eCollection 2021.
Metaplastic breast cancer (MBC) is a rare tumor with aggressive biological behavior. This study aimed to evaluate the efficacy of post-mastectomy radiotherapy (PMRT) on patients with low-risk (T1N0M0), intermediate-risk (T1-2N1M0 and T3N0M0), and high-risk (T1-4N2-3M0 and T4N0-1M0) MBC propensity-score matching (PSM).
We analyzed information from the Surveillance, Epidemiology, and End Results (SEER) public-use database from 1975 to 2016 for MBC incidence trends and compared overall survival (OS) and breast cancer-specific survival (BCSS) between groups of MBC women diagnosed from 2001 to 2016 using Kaplan-Meier analysis and the multivariate Cox proportional model. PSM was used to make 1:1 case-control matching.
Joinpoint analyses identified 1984 and 2003 as the inflection points among 4,672 patients. 1,588 (42.4%) of the 3,748 patients diagnosed with MBC between 2001 and 2016 received PMRT. According to multivariate analyses, PMRT provided better OS (p < 0.001) and BCSS (p < 0.001) before PSM, and better prognosis after PSM (n = 2528) for patients receiving PMRT (n = 1264) compared to those without PMRT (OS, p < 0.001 and BCSS, p < 0.001). When stratifying the case-control matching patients into low-risk, intermediate-risk, and high-risk groups, PMRT could improve BCSS compared with that in non-PMRT patients in the high-risk groups; it also improved OS in both the intermediate- and high-risk groups.
Per findings of the PSM analysis, PMRT could provide better BCSS in high-risk groups, and better OS in intermediate- and high-risk groups.
化生性乳腺癌(MBC)是一种具有侵袭性生物学行为的罕见肿瘤。本研究旨在评估保乳术后放疗(PMRT)对低风险(T1N0M0)、中度风险(T1-2N1M0和T3N0M0)和高风险(T1-4N2-3M0和T4N0-1M0)MBC患者倾向评分匹配(PSM)的疗效。
我们分析了1975年至2016年监测、流行病学和最终结果(SEER)公共使用数据库中MBC的发病趋势,并使用Kaplan-Meier分析和多变量Cox比例模型比较了2001年至2016年诊断的MBC女性组之间的总生存期(OS)和乳腺癌特异性生存期(BCSS)。PSM用于进行1:1病例对照匹配。
连接点分析确定1984年和2003年为4672例患者中的转折点。2001年至2016年诊断为MBC的3748例患者中,1588例(42.4%)接受了PMRT。根据多变量分析,在PSM之前,PMRT提供了更好的OS(p < 0.001)和BCSS(p < 0.001),与未接受PMRT的患者相比,接受PMRT的患者(n = 1264)在PSM后(n = 2528)预后更好(OS,p < 0.001;BCSS,p < 0.001)。当将病例对照匹配患者分为低风险、中度风险和高风险组时,与高风险组中未接受PMRT的患者相比,PMRT可改善BCSS;它还改善了中度和高风险组的OS。
根据PSM分析结果,PMRT可在高风险组中提供更好的BCSS,并在中度和高风险组中提供更好的OS。